The global blood typing market size was estimated to be USD 2.20 billion in 2023 and is expected to reach USD 6.50 billion by 2034 with a CAGR of 10.36% during the forecast period 2024-2034. The market will grow due to rising chronic disease rates, rising awareness of and adoption of preventive healthcare, advances in blood typing technology, increasing need for transfusions, and government initiatives and regulations.
Technological advancements in blood typing methods have significantly enhanced the efficiency and accuracy of laboratory practices. The introduction of automated systems, such as Bio-Rad's IH-500 NEXT, which was launched in May 2023, exemplifies this trend by offering a fully automated blood typing system designed to improve immunohematology lab efficiency and optimize result interpretation110. Modern molecular methods, including PCR-based assays, microarray technologies, and next-generation sequencing, provide faster and more precise results, thereby reducing human error and improving safety512. These innovations enable high throughput capabilities for large-scale blood typing needs, addressing both routine and complex blood type screening challenges511. Overall, these advancements position laboratories to better meet clinical demands while enhancing the safety of blood transfusions and treatments.
By product and services, the reagents and consumables segment accounted for the highest revenue-grossing segment in the global blood typing market in 2023 owing to the constant demand for blood typing tests and the need for regular replenishment of consumables such as reagents, test kits, and other disposable supplies. For instance, The U.S. Food and Drug Administration ("FDA") has listed Inspira Technologies OXY B.H.N. Ltd. a pioneer in life-support technology innovation, in August 2024. The medical cart (INSPIRATM CART), which has been specially made for use with the INSPIRATM ART100 system, is now available. Inspira hopes to improve healthcare delivery in a range of clinical scenarios by combining state-of-the-art technology and operational efficiency in a dynamic way. This will turn the INSPIRATM ART100 system into a mobile workstation that helps medical professionals provide rapid medical care. Additionally, the services segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing outsourcing of blood testing services by hospitals and clinics to specialized laboratories, as well as the rise in demand for personalized and accurate blood typing services.
By test type, the antibody screening segment accounted for the highest revenue-grossing segment in the global blood typing market in 2023 owing to the critical role of antibody screening in detecting antibodies in blood, ensuring compatibility in transfusions, and preventing adverse reactions in patients. For instance, Novo Nordisk today introduced The Power of Wegovy®, a new nationwide campaign, in June 2024. The campaign's objectives are to inform people about the clinical evidence supporting Wegovy® (semaglutide) 2.4 mg injectable and to highlight the sense of community empowerment that comes from not having to control their weight alone. Additionally, the HLA typing segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing importance of HLA typing in organ transplantation, bone marrow transplants, and immunotherapy, driving the need for precise HLA matching for successful outcomes.
By technique, the PCR-based and microarray-based segment accounted for the highest revenue-grossing segment in the global blood typing market in 2023 owing to the high accuracy, speed, and efficiency of these advanced techniques in identifying blood groups and detecting genetic variations. For instance, in May 2024, the world leader in supporting science, Thermo Fisher Scientific Inc., unveiled the first-ever Applied BiosystemsTM AxiomTM BloodGenomiXTM Array* and Software, which enables more accurate blood genotyping in clinical research. The novel array supports future developments in donor blood matching for expanded phenotypes by detecting the majority of extended and unusual blood groups, tissue (HLA), and platelet (HPA) types in a single, high-throughput assay. Additionally, the assay-based techniques segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of high-throughput and automated assay techniques in blood typing for better accuracy and faster results in laboratory settings.
By application, the diagnostic testing segment accounted for the highest revenue-grossing segment in the global blood typing market in 2023 owing to the wide usage of blood typing in diagnosing conditions like hemolytic diseases, anemia, and for blood transfusion preparation. For instance, in March 2023 Werfen paid almost USD 2 billion to acquire Immucor, Inc., growing its range of specialized diagnostics in the markets for transfusion and transplants. Additionally, the organ transplants segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing number of organ transplants globally and the critical need for precise blood and tissue typing for donor-recipient matching.
By end-user, the diagnostic laboratories segment accounted for the highest revenue-grossing segment in the global blood typing market in 2023 owing to the high volume of blood typing tests performed in these facilities for various medical and research purposes. For instance, Alba by Quotient joined the European markets in June 2023 when it expanded into the Netherlands and Sweden. supplying dependable service, knowledgeable assistance, and top-notch blood bank reagents. Leveraging more than 30 years of experience, Quotient also offers the MosaiQ sophisticated diagnostics solution. Additionally, the blood banks segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising number of blood donations, advancements in blood storage, and the need for reliable blood typing before transfusions.
North American region is anticipated for the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, high adoption of advanced blood typing technologies, the presence of key market players, and a rising number of blood transfusions and organ transplants in the region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the growing healthcare expenditure, increasing awareness of blood donation, rapid advancements in healthcare infrastructure, and rising demand for blood typing due to a large population and increasing prevalence of chronic diseases. For instance. Gene therapy company Genprex, Inc., which is in the clinical stage and aims to provide patients with diabetes and cancer with life-changing treatments, announced in September 2024 that it will be transferring its diabetes gene therapy assets and its diabetes clinical development program into a new wholly-owned subsidiary or "NewCo" In order to cure Type 1 (T1D) and Type 2 diabetes (T2D), NewCo would concentrate on creating and releasing GPX-002, a diabetes gene therapy medication candidate.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Technological advancements in blood typing methods have significantly enhanced the efficiency and accuracy of laboratory practices. The introduction of automated systems, such as Bio-Rad's IH-500 NEXT, which was launched in May 2023, exemplifies this trend by offering a fully automated blood typing system designed to improve immunohematology lab efficiency and optimize result interpretation110. Modern molecular methods, including PCR-based assays, microarray technologies, and next-generation sequencing, provide faster and more precise results, thereby reducing human error and improving safety512. These innovations enable high throughput capabilities for large-scale blood typing needs, addressing both routine and complex blood type screening challenges511. Overall, these advancements position laboratories to better meet clinical demands while enhancing the safety of blood transfusions and treatments.
By product and services, the reagents and consumables segment accounted for the highest revenue-grossing segment in the global blood typing market in 2023 owing to the constant demand for blood typing tests and the need for regular replenishment of consumables such as reagents, test kits, and other disposable supplies. For instance, The U.S. Food and Drug Administration ("FDA") has listed Inspira Technologies OXY B.H.N. Ltd. a pioneer in life-support technology innovation, in August 2024. The medical cart (INSPIRATM CART), which has been specially made for use with the INSPIRATM ART100 system, is now available. Inspira hopes to improve healthcare delivery in a range of clinical scenarios by combining state-of-the-art technology and operational efficiency in a dynamic way. This will turn the INSPIRATM ART100 system into a mobile workstation that helps medical professionals provide rapid medical care. Additionally, the services segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing outsourcing of blood testing services by hospitals and clinics to specialized laboratories, as well as the rise in demand for personalized and accurate blood typing services.
By test type, the antibody screening segment accounted for the highest revenue-grossing segment in the global blood typing market in 2023 owing to the critical role of antibody screening in detecting antibodies in blood, ensuring compatibility in transfusions, and preventing adverse reactions in patients. For instance, Novo Nordisk today introduced The Power of Wegovy®, a new nationwide campaign, in June 2024. The campaign's objectives are to inform people about the clinical evidence supporting Wegovy® (semaglutide) 2.4 mg injectable and to highlight the sense of community empowerment that comes from not having to control their weight alone. Additionally, the HLA typing segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing importance of HLA typing in organ transplantation, bone marrow transplants, and immunotherapy, driving the need for precise HLA matching for successful outcomes.
By technique, the PCR-based and microarray-based segment accounted for the highest revenue-grossing segment in the global blood typing market in 2023 owing to the high accuracy, speed, and efficiency of these advanced techniques in identifying blood groups and detecting genetic variations. For instance, in May 2024, the world leader in supporting science, Thermo Fisher Scientific Inc., unveiled the first-ever Applied BiosystemsTM AxiomTM BloodGenomiXTM Array* and Software, which enables more accurate blood genotyping in clinical research. The novel array supports future developments in donor blood matching for expanded phenotypes by detecting the majority of extended and unusual blood groups, tissue (HLA), and platelet (HPA) types in a single, high-throughput assay. Additionally, the assay-based techniques segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of high-throughput and automated assay techniques in blood typing for better accuracy and faster results in laboratory settings.
By application, the diagnostic testing segment accounted for the highest revenue-grossing segment in the global blood typing market in 2023 owing to the wide usage of blood typing in diagnosing conditions like hemolytic diseases, anemia, and for blood transfusion preparation. For instance, in March 2023 Werfen paid almost USD 2 billion to acquire Immucor, Inc., growing its range of specialized diagnostics in the markets for transfusion and transplants. Additionally, the organ transplants segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing number of organ transplants globally and the critical need for precise blood and tissue typing for donor-recipient matching.
By end-user, the diagnostic laboratories segment accounted for the highest revenue-grossing segment in the global blood typing market in 2023 owing to the high volume of blood typing tests performed in these facilities for various medical and research purposes. For instance, Alba by Quotient joined the European markets in June 2023 when it expanded into the Netherlands and Sweden. supplying dependable service, knowledgeable assistance, and top-notch blood bank reagents. Leveraging more than 30 years of experience, Quotient also offers the MosaiQ sophisticated diagnostics solution. Additionally, the blood banks segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising number of blood donations, advancements in blood storage, and the need for reliable blood typing before transfusions.
North American region is anticipated for the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, high adoption of advanced blood typing technologies, the presence of key market players, and a rising number of blood transfusions and organ transplants in the region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the growing healthcare expenditure, increasing awareness of blood donation, rapid advancements in healthcare infrastructure, and rising demand for blood typing due to a large population and increasing prevalence of chronic diseases. For instance. Gene therapy company Genprex, Inc., which is in the clinical stage and aims to provide patients with diabetes and cancer with life-changing treatments, announced in September 2024 that it will be transferring its diabetes gene therapy assets and its diabetes clinical development program into a new wholly-owned subsidiary or "NewCo" In order to cure Type 1 (T1D) and Type 2 diabetes (T2D), NewCo would concentrate on creating and releasing GPX-002, a diabetes gene therapy medication candidate.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Product and Services, Test Type, Technique, Application, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Blood Typing Market Report 2023 - 2034
Blood Typing Market Analysis & Forecast by Product and Services 2023 - 2034 (Revenue USD Bn)
- Instruments
- Reagents & Consumables
- Services
Blood Typing Market Analysis & Forecast by Test Type 2023 - 2034 (Revenue USD Bn)
- Antibody Screening
- HLA Typing
- Cross-matching
- ABO Blood Tests
- Others
Blood Typing Market Analysis & Forecast by Technique 2023 - 2034 (Revenue USD Bn)
- PCR Based and Microarray Based
- Assay Based Technique
- Massively Parallel Sequencing
- Other
Blood Typing Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Blood Transfusions
- Organ Transplants
- Diagnostic Testing
Blood Typing Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Hospitals & Clinics
- Diagnostic Laboratories
- Blood Banks
- Others
Blood Typing Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Blood Typing Market: Product and Services Estimates & Trend Analysis
8. Blood Typing Market: Test Type Estimates & Trend Analysis
9. Blood Typing Market: Technique Estimates & Trend Analysis
10. Blood Typing Market: Application Estimates & Trend Analysis
11. Blood Typing Market: End-user Estimates & Trend Analysis
12. Regional Market Analysis
13. North America Blood Typing Market
14. Europe Global Blood Typing Market
15. Asia Pacific Global Blood Typing Market
16. Latin America Global Blood Typing Market
17. MEA Global Blood Typing Market
18. Competitor Analysis
19. Company Profiles
Companies Mentioned
- Grifols S.A.
- Thermo Fisher Scientific Inc.
- Roche Diagnostics
- Bio-Rad Laboratories Inc.
- Ortho Clinical Diagnostics Inc.
- Beckman Coulter Inc.
- Abbott Laboratories
- Siemens Healthineers
- Becton
- Dickinson and Company (BD)
- HemoCue AB
- Cardinal Health Inc.
- Sysmex Corporation
- F. Hoffmann-La Roche AG
- Greiner Bio-One International GmbH
- Kabe Labortechnik GmbH.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | December 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 2.2 Billion |
| Forecasted Market Value ( USD | $ 6.5 Billion |
| Compound Annual Growth Rate | 10.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 16 |
